Nicholas Saraceno

4 days ago | pharmaceuticalcommerce.com | Nicholas Saraceno

Key TakeawaysTariffs could spike drug costs: Proposed 25% tariffs on pharmaceuticals may raise US drug prices by up to 12.9% and cost the industry an estimated $51 billion annually. Supply chain disruption is growing: Pharma and medtech sectors face significant supply chain strain, including delays and pricing spikes, due to tariff volatility and reliance on global manufacturing.

5 days ago | pharmaceuticalcommerce.com | Nicholas Saraceno

In a video interview with Pharma Commerce, Scott Tillman, Logility’s senior vice president of innovation, addresses the gap between high interest in generative AI (GenAI) and its relatively low adoption in supply chain-specific applications, as highlighted in Logility’s Supply Chain Horizons 2025 Market Report. He identified several key reasons for this disconnect. First, many companies experience “paralysis by analysis” due to the rapidly evolving technology landscape.

6 days ago | pharmaceuticalcommerce.com | Nicholas Saraceno

In a video interview with Pharma Commerce, Scott Tillman, Logility’s senior vice president of innovation, addresses the gap between high interest in generative AI (GenAI) and its relatively low adoption in supply chain-specific applications, as highlighted in Logility’s Supply Chain Horizons 2025 Market Report. He identified several key reasons for this disconnect. First, many companies experience “paralysis by analysis” due to the rapidly evolving technology landscape.

6 days ago | pharmaceuticalcommerce.com | Nicholas Saraceno

Key TakeawaysTo meet rising demand, Bora Pharmaceuticals is expanding its Baltimore facility by installing an automated vial, syringe, and cartridge line by 2026, enhancing its capabilities for small-scale, high-value drug production. The expansion supports increased demand for fill-finish services related to potent drugs and treatments for rare and orphan diseases, boosting Bora’s flexibility and scalability across clinical and commercial projects.

1 week ago | pharmaceuticalcommerce.com | Nicholas Saraceno

In a video interview with Pharma Commerce, Scott Tillman, Logility’s senior vice president of innovation, addresses the gap between high interest in generative AI (GenAI) and its relatively low adoption in supply chain-specific applications, as highlighted in Logility’s Supply Chain Horizons 2025 Market Report. He identified several key reasons for this disconnect. First, many companies experience “paralysis by analysis” due to the rapidly evolving technology landscape.